GLP-1s for Addiction: Can They Reduce Drug Cravings?

Why Researchers Think GLP-1s Might Do More Than Suppress Appetite

If you take Ozempic or Wegovy for weight loss, you may have noticed something unexpected: cravings for alcohol, sweets, or even cigarettes seemed to fade along with your appetite. You are not imagining it, and you are not alone.

Patients and clinicians started reporting this pattern shortly after GLP-1 medications became widely used for obesity. Now researchers are taking those anecdotal reports seriously. Programs across the United States, including one based in Rhode Island, are running structured studies to find out whether GLP-1 receptor agonists can meaningfully reduce cravings for addictive substances.

This is still early-stage science. But the early signals are interesting enough that it's worth understanding what we know, what we don't, and what it might mean for you or someone you care about.

The Biology Connecting Food Cravings and Drug Cravings

To understand why GLP-1s might help with addiction, you need a quick look at how the brain processes reward.

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after eating. It signals fullness to the brain, slows digestion, and helps regulate blood sugar. But GLP-1 receptors are not only found in the stomach and pancreas. They are also present in the brain's mesolimbic system, sometimes called the reward pathway.

This is the same neural circuit that lights up when someone uses alcohol, opioids, nicotine, or other addictive substances. When drugs activate this pathway, they flood it with dopamine, the chemical associated with pleasure and motivation. Over time, the brain adapts, and the person needs more of the substance just to feel normal.

Researchers believe that GLP-1 receptor activation in this brain region may dampen the dopamine response to addictive substances. In animal studies, rodents given GLP-1 receptor agonists drank less alcohol, self-administered fewer opioids, and showed less interest in cocaine when given the option.

The leap from rodent models to humans is not automatic. But the mechanism is plausible, and the human anecdotal reports are adding up.

What the Rhode Island Program Is Actually Doing

Rhode Island has one of the most active addiction medicine communities in the country, shaped in large part by years of dealing with the opioid crisis. A clinical program there is now exploring whether adding a GLP-1 medication to standard addiction treatment changes outcomes for patients.

The structure of such programs typically involves enrolling adults who have a diagnosed substance use disorder and who may also have obesity or metabolic conditions that independently justify GLP-1 treatment. Participants receive the GLP-1 medication alongside existing evidence-based therapies, such as medications for opioid use disorder (MOUD) like buprenorphine, behavioral counseling, or both.

Researchers are tracking several things: self-reported craving intensity, rates of relapse, substance use frequency, and biological markers where possible. The goal is not to replace existing addiction treatments but to see whether a GLP-1 can serve as a useful add-on that makes recovery more sustainable.

This is a model that matters for patients to understand. GLP-1s are not being tested as a standalone cure for addiction. They are being studied as one piece of a larger treatment puzzle.

What Human Evidence Exists So Far?

Formal clinical trials in humans are still underway, but some early data has surfaced from observational studies and smaller trials.

A 2023 study published in the journal Addiction found that people with alcohol use disorder who were also taking semaglutide reported fewer heavy drinking days compared to those not taking the medication. The effect was modest but statistically meaningful.

Separate research from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) has supported funding for trials specifically targeting alcohol use disorder with GLP-1 drugs, citing the preclinical evidence as a strong enough signal to warrant human testing.

For opioids, the data is thinner but trending in a similar direction. Retrospective analyses of large insurance claim databases have found lower rates of opioid-related hospitalizations among patients who were prescribed GLP-1 medications, compared to similar patients who were not. These are correlational findings, not proof of causation, but they add to the picture.

Nicotine is another area drawing attention. Some patients taking semaglutide informally report that they stopped smoking or found it easier to quit, though controlled trials in this area are still getting started.

The Substances Being Studied

Not all substances are being investigated equally. Here is a snapshot of where research attention is currently focused.

What GLP-1 Medications Are Being Studied for This Purpose?

Most of the research centers on semaglutide, the active ingredient in Ozempic and Wegovy. Semaglutide is the most widely used GLP-1 receptor agonist at present, which makes it the practical choice for researchers who want to recruit large enough populations.

Liraglutide (Victoza, Saxenda), an older GLP-1 drug, has been studied in some preclinical addiction models as well, largely because it was available earlier. Results have been consistent with what is seen in semaglutide research.

(tirzepatide), which acts on both GLP-1 and GIP receptors, is a newer addition to the GLP-1 family and is generating its own curiosity. Because it appears to produce stronger effects on appetite and weight than semaglutide alone, researchers are theorizing whether it might also have a stronger effect on reward signaling. Formal addiction-focused trials with tirzepatide are in earlier stages.

It is worth being clear: none of these drugs are approved by the FDA for treating addiction or substance use disorders. They are approved for type 2 diabetes and, in higher-dose formulations, for chronic weight management. Any use in addiction treatment right now would be considered off-label or within a clinical research setting.

What This Means If You Are Currently Taking a GLP-1

If you are already prescribed a GLP-1 medication for weight loss or diabetes and you have a personal or family history of substance use issues, a few things are worth knowing.

First, some patients do spontaneously report reduced cravings for alcohol or other substances while on these medications. This is not guaranteed, and it is not a reason to stop any existing addiction treatment you are receiving.

Second, if you have noticed changes in your relationship with alcohol or other substances since starting a GLP-1, tell your prescriber. That information is genuinely useful to the research community and may prompt a useful conversation about your overall care.

Third, if you are managing active addiction alongside obesity or type 2 diabetes, you may qualify for a clinical trial studying this connection. Talk to your doctor about whether that makes sense for your situation.

You should not use GLP-1 medications as a replacement for proven addiction treatments like medication-assisted treatment (MAT), behavioral therapy, or peer support. The research is promising but not mature enough to support that substitution.

Important Considerations Around Safety and Access

GLP-1 medications come with their own side effect profile, most commonly nausea, vomiting, and gastrointestinal discomfort, especially in the early weeks of treatment. These effects are usually manageable with a gradual dose escalation, but they matter more in the context of addiction treatment.

People in early recovery often face nutritional challenges, disrupted sleep, and heightened sensitivity to physical discomfort. Adding a medication that can cause nausea requires careful clinical management. An addiction medicine specialist and a prescribing physician should ideally coordinate care if a GLP-1 is being used in this context.

Cost is also a real barrier. GLP-1 medications can run $900 to $1,300 per month without insurance coverage. Most insurance plans do not currently cover these drugs for addiction-related uses, and even weight loss coverage varies considerably. If cost is a concern, checking available GLP-1 Coupons and comparing providers can make a meaningful difference in what you pay out of pocket.

Clinical trial participation, if you qualify, is one way to access a GLP-1 medication without paying the retail price. ClinicalTrials.gov is a good starting point for finding open studies.

Questions to Ask Your Doctor

If this research has you curious about your own situation, here are some specific questions worth raising at your next appointment

1. I have noticed changes in my cravings for alcohol or other substances since starting my GLP-1 medication. Is that a recognized effect of this drug class, and is it something you want me to document or monitor more closely?
2. I have a history of substance use. Does that affect how you would approach my GLP-1 dosing, titration schedule, or monitoring plan, particularly given that nausea and GI side effects can be harder to manage in early recovery?
3. Are there any clinical trials studying GLP-1 medications in the context of addiction treatment that I might qualify for, and would participating make sense given my current health situation?
4. If I am already receiving medication-assisted treatment for opioid use disorder or another addiction, is there any interaction risk or clinical consideration I should be aware of before starting or continuing a GLP-1 medication?
5. Would you be comfortable coordinating with my addiction medicine provider if I am using a GLP-1 medication alongside an existing treatment program, so that both sides of my care are aligned?
6. If my GLP-1 medication appears to be reducing my cravings for substances, is that a reason to adjust my existing addiction treatment plan, or should I continue both treatments independently and discuss changes only with my addiction specialist?
7. Given that this research area is still early, what would you need to see in terms of my clinical response before feeling confident recommending a GLP-1 as part of a broader addiction recovery strategy?

Good providers will welcome these questions. If you are looking for a clinician who is both knowledgeable about GLP-1s and open to this emerging evidence, comparing GLP-1 providers can help you find someone aligned with current research.